Introduction {#Sec1}
============

Coenzyme Q10 (CoQ), also known as ubiquinone, is crucial for the function of mitochondrial respiratory chain complexes. Currently, the pathway of CoQ biosynthesis is known to involve at least 18 proteins. Primary CoQ deficiencies in humans involve genetic mutations in *COQ2*, *PDSS1*, *PDSS2*, *COQ8A*, *COQ9*, *COQ6*, *COQ4*, or *COQ7*.^[@CR1]^

The primary CoQ10 deficiency-7 (COQ10D7, MIM: 616276) is caused by autosomal-recessive mutations in *COQ4*. *COQ4* is hypothesized to take part in stabilizing the CoQ complex.^[@CR2]^ To date, biallelic *COQ4* mutations have been described in 16 patients from 11 unrelated families. They were reported in two case series (with five to six cases each) and three case reports. The patients described had common features of cardiomyopathy, encephalopathy, lactic acidosis often with a neonatal onset, and death in the neonatal or infantile period.^[@CR2]--[@CR4]^ Two siblings of childhood onset presenting with spinocerebellar ataxia and stroke-like episodes^[@CR5]^ and two Chinese siblings with neonatal onset of dystonia, seizures, lactic acidosis, and cerebellar atrophy were described in recent case reports.^[@CR6]^

In this report, we have 11 patients (4 males and 7 females) from 9 unrelated families who were managed by the Medical Genetics division of the Department of Paediatrics and Adolescent Medicine at the University of Hong Kong and the Department of Medical Genetics and Pediatrics at the National Taiwan University Hospital in the period of 2014--2018. They presented with two overlapping phenotypes: the classical neonatal-onset encephalo-cardiomyopathy and infantile-onset encephalopathy with or without cardiomyopathy. They were diagnosed as COQ10D7 due to homozygous or compound heterozygous *COQ4* mutations. All genetic diagnoses were made by whole-exome sequencing (WES) except Patient 4, Patient 5, and Patient 11 due to their known family history and recognizable features of COQ10D7. More importantly, we have identified a Chinese-specific *COQ4* founder mutation in 10 subjects, 5 of whom are homozygous for that mutation.

Case reports {#Sec2}
============

The study was approved by the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW12-211) and the National Taiwan University Hospital (201703073RINB). Written informed consent was obtained from subjects or their parents. A summary of the clinical, biochemical, and radiological characteristics of the 11 patients with *COQ4* mutations identified is presented in Table [1](#Tab1){ref-type="table"}. Patients 1--5 had the classical neonatal-onset phenotype described by Brea-Calvo et al. and Chung et al.,^[@CR2],[@CR3]^ whereas Patients 6--11 had later onset and more heterogeneous features. The frequency of distinct phenotypes compared with previous studies is summarized in Table [2](#Tab2){ref-type="table"}. The corresponding MRI (magnetic resonance imaging) images are presented in Fig. [1](#Fig1){ref-type="fig"}. The pedigrees of the nine families are presented in Fig. [2](#Fig2){ref-type="fig"}.Table 1Summary of characteristics of 11 patients with *COQ4* mutations in this study and previously reported casesPhenotype groupNeonatal-onset encephalo-cardiomyopathyReferenceThis studyBrea-Calvo et al.^[@CR2]^Family 1Family 3Subject12345S1S2S3S4S5SexMaleMaleFemaleFemaleFemaleMaleFemaleFemaleFemaleMaleAge at presentationNeonatalNeonatalNeonatalAt birth2 monthsNeonatalNeonatalNeonatalNeonatalInfantileLast follow-upPassed away at 8 months (redirection of care)Passed away at 2.5 days (unknown cause)9 monthsNow 4 years 6 monthsPassed away at 1 year 1 month (respiratory failure)Passed away at 4 h after birthPassed away at 1 dayPassed away at 3 daysPassed away at 2 daysStill alive at age 18 years*CoQ4* mutationc.370G\>A/c.402+1G\>Cc.370G\>A/c.402+1G\>CHomozygous c.370G\>Ac.370G\>A/c.402+1G\>Cc.370G\>A/c.402+1G\>CHomozygous c.433C\>Gc.421C\>T/c.718C\>Tc.155T\>C/c.521_523delCCAc.155T\>C/c.521_523delCCAHomozygous c.190C\>THypotonia√×√√√√×√××Seizures√×√√√××√√√Cardiomyopathy√√√√×√√×××Other presented problemsSevere GDD, cortical visual impairment, bilateral severe to profound hearing impairment, myopathyApneaSevere GDDSevere DD, poor oromotor functionDDAreflexiaAcrocyanosisRespiratory failureBradycardiaSevere IUGRRespiratory failureRespiratory distress syndromeDistal arthrogryposisNeonatal respiratory distressProgressive motor deterioration after 10 months old, spastic ataxic gait at age 3 yearsWheelchair bound by age 6 yearsProgressive swallowing difficulties requiring gastrostomyCognitive deteriorationPolyneuropathy with slow conductionProgressive scoliosisTiming of MRI or other imaging3 weeks and 3 months---7 weeks7 days and 9 months---------USG brain at birthUSG brain at birthAge 12 and 17 yearsMRI brain or other imaging findingsSymmetrical T1 and T2 hyperintensity with restricted diffusion at bilateral lentiform nuclei, subsequently infarcts with cystic changes. Foci of restricted diffusion also at bilateral frontal white matter. MRS: raised lactate peaks at bilateral basal ganglia and cerebral white matter. Mild cerebellar hypoplasia---Mild cerebellar hypoplasia, mild thinning of corpus callosumNeonatal stage: symmetrical T1 hyperintensity at bilateral basal ganglia, mild cerebellar hypoplasia, later with generalized progressive cerebellar and cerebral atrophy with diffuse white matter loss, thinning of corpus callosum. Cystic changes within cerebral white matter, bilateral basal ganglia, thalami. MRS: raised lactate peaks at bilateral basal ganglia---------USG brain: cerebellar hypoplasiaAutopsy: Severe olivopontocerebellar and thalamic hypoplasia and scattered cavitations in the white matterUSG brain: cerebellar hypoplasiaMRI at age 12 years: bilateral increased signal intensity in FLAIR and T2W sequencing in both occipital cortical and juxtacortical areasMRI at age 17 years cerebellar atrophy, widened ventricular space, scars from cortical necrotic lesions in both occipital areasLactic acidosis√√√√√√√√√×Effect of CoQ10 supplementNo significant improvementNo significant improvementCardiac function stableNo significant improvementNo significant improvementNot usedNot usedNot usedNot usedNot usedPhenotype groupNeonatal-onset encephalo-cardiomyopathyReferenceChung et al.^[@CR3]^Sondheimer et al.^[@CR4]^Bosch et al.^[@CR5]^Lu et al.^[@CR6]^SubjectFamily 1Family 3Family 1Family 1Proband 1Sibling of Proband 1Proband 2Proband 3Sibling of Proband 3Proband 4PatientPatient 1Patient 2Patient II-1Patient II-2SexFemaleFemaleFemaleFemaleFemaleFemaleMaleMaleFemaleMaleFemaleAge at presentationNeonatalNeonatalNeonatalNeonatalNeonatalNeonatalNeonatalDiagnosed at age 138 months2 months2 monthsLast follow-upPassed away at 2 months (redirection of care)Passed away at 4 daysPassed away at 4 daysPassed away at 19 monthsPassed away at 10 weeksPassed away at 7 weeksPassed away at 4 months---3 years 7 months (oversea adoption)Passed away at 5 months3 years and 8 months*CoQ4* mutationc.245T\>A/c.473G\>AHomozygous c.718C\>THomozygous c.718C\>Tc.197_198delGCinsAA/c.202G\>Cc.197_198delGCinsAA/c.202G\>CHomozygous c.718C\>Tc.23_33del11/c.331G\>T/c.356C\>THomozygyous c.230C\>Tc.550T\>C/c.402+1G\>AHomozygous c.370G\>AHomozygous c.370G\>AHypotonia√---√√√√√------××Seizures√√ (Suspected)×√××√√√√√Cardiomyopathy√√√√×√√--------- (cardiomegaly on chest X ray)×Other presented problems---IUGRModerate cerebellar hypoplasiaIUGRModerate cerebellar hypoplasiaFeeding difficulties,GDD, microcephalyFeeding difficultiesFeeding difficulties, left hip dysplasiaGastroesophageal reflux requiring fundoplication, delayed visual maturation without structural abnormality of the eyes, bilateral hearing loss, and absence of developmentDelayed speechTremor since age 4 yearsProgressive motor deterioration; wheelchair bound by age 12 years, then dysarthriaSpastic tetraparesisAtaxia of upper and lower limbsAbnormal cognitive developmentTremor since age 10 yearsModerate intellectual disabilityFrequent fallsRight hemi-anopsiaSecond stroke-like episode at age 14 yearsDystonia since birthHearing impairmentFeeding difficultyProgressive motor deterioration Failure to thriveDystonia since birthHearing impairmentFeeding difficultyProgressive motor deteriorationNystagmus at 2 monthsTiming of MRI or other imagingEarly neonatal period------Day 1Fetal MRI at 30 weeks andDay 2UnknownFirst week and tenth week5 years10 years13 years2 months1 month, 4 months and 3 years and 8 monthsMRI brain or other imaging findingsSmall cerebellar size and diffuse T2 white matter hyperintensityMRS decreased *N*-acetylaspartate and a lactate peakAutopsy: Cerebellar and brainstem hypoplasia and microdysgenesisAutopsy: Cerebellar and brainstem hypoplasia and microdysgenesisCerebellar hypoplasia, prominent extra axial space in posterior fossa and mild lateral ventricle enlargementFetal MRI: normal intracranial anatomy, transverse cerebellar diameter 10--15th percentileMRI on Day 2: decreased cerebellar hemisphere volumeNormalFirst week: focal regions of cortical increased T1 signal and magnetic resonance spectroscopy identified enlarged lactate peaksTenth week: microcephaly with volume loss and increasing prominence of lactate peaksSuspected tectal glioma (treated with radiotherapy)Age 10 years: Cavernoma in the left parietal lobeAge 13 years: Lesion at left occipital lobe with clear diffusion restrictionSlightly widened frontal and temporal lobes1 month: normal4 months: found lesions in midbrain and basal ganglia3 years and 8 months: CT brain: symmetrical, patchy, low density shadow in bilateral basal ganglia and diffuse brain atrophyLactic acidosis√√√×√×√------√√Effect of CoQ10 supplementImprovement after 2 weeks of age but recurrent episode of metabolic and hemodynamic decompensationNot usedNot usedNot usedNot usedNo significant improvementNot usedWalk test stable over the period of a yearWalk test stable over the period of a yearNo significant improvementImproved seizure control but no improvement in dystonia and motor developmentPhenotype groupInfantile-onset encephalo-cardiomyopathyReferenceThis studyFamily 2Subject67891011SexMaleFemaleFemaleMaleFemaleFemaleAge at presentation8 monthsSince early infancySince early infancy2 months2 months4 monthsLast follow-up3 years 7 months (overseas adoption)Passed away at 3 years 6 months (unknown cause)3 years 3 months8 years1 year 6 monthsPassed away at 1 year 8 months (septic shock)*CoQ4* mutationc.550T\>C/c.402+1G\>AHomozygous c.370G\>Ac.370G\>A/c.371G\>THomozygous c.370G\>AHomozygous c.370G\>AHomozygous c.370G\>AHypotonia√×××√√Seizures××√√√√Cardiomyopathy××××√√Other presented problemsSevere GDD, generalized dystonia, cortical visual impairment, impaired oromotor functionSevere GDD, generalized dystonia and spasticity, cortical visual impairment, impaired oromotor functionSevere GDD, generalized dystonia and spasticity, cortical visual impairmentDDSevere DD, bilateral cortical blindnessDD, intermittent spasticity, impaired oromotor functionTiming of MRI or other imagingDay 21, Day 40, and 1 year 4 months6 months6, 7, and 35 months32 months14 months1 year 2 monthsMRI brain or other imaging findingsMild cerebral atrophy with bilateral frontal predominanceSevere cerebral atrophyMild cerebral and cerebellar hypoplasia. Small focus of T2 and FLAIR hyperintensity at the left lentiform nucleus at 35 months. MRS: raised lactate peaks at bilateral basal ganglia and frontal white matter at 6 months, normalized by 7 monthsModerate cerebellar atrophy without isolated vermian hypoplasia, cerebral atrophy, symmetrical loss of cerebral white matter particularly in bilateral frontal and anterior temporal regions. Corpus callosum was thinned, basal ganglia and pons unremarkableMild thinning of corpus callosumMild cerebellar atrophy and cerebral atrophy, white matter cystic changes with bilateral frontal and anterior temporal predominance. Corpus callosum thinning, preserved basal ganglia and brainstemLactic acidosis√√√√√×Effect of CoQ10 supplementNo significant improvementNo significant improvementSubjective improvement in responseStable conditionSome improvement in seizure control and developmentNot used*MRS* magnetic resonance spectroscopy, *MRI* magnetic resonance imaging, *FLAIR* fluid-attenuated inversion recovery, *GDD* global developmental delay, *DD* developmental delay, *IUGR* intrauterine growth restriction, *USG* ultrasoundTable 2Phenotypic comparison between patients in this study and previously reported casesThis studyChung et al.^[@CR3]^Brea-Calvo et al.^[@CR2]^Sondheimer et al.^[@CR4]^Bosch et al.^[@CR5]^Lu et al.^[@CR6]^Number of subjects1165122Female-to-male ratio7:46:03:20:11:11:1Age of presentationBirth to 8 monthsBirth to day 1Birth to 6 h1 day4--9 years1--2 monthsNeonatal onset5/11 (45%)6/6 (100%)4/5 (80%)1/1 (100%)0/2 (0%)2/2 (100%)Infantile onset6/11 (54%)0/6 (0%)1/5 (20%)0/1 (0%)0/2 (0%)0/2 (0%)Childhood onset0/11 (0%)0/6 (0%)0/5 (0%)0/1 (0%)2/2 (100%)0/2 (0%)Respiratory distress5/11 (45%)6/6 (100%)^a^4/4 (100%)1/1 (100%)---2/2 (100%)Cardiomyopathy6/11 (54%)5/6 (83%)2/5 (40%)1/1 (100%)---1/2 (50%)Hypotonia7/11 (64%)^a^5/5 (100%)2/5 (40%)1/1 (100%)------Dystonia2/11 (18%)------------2/2 (100%)Seizures8/11 (73%)3/6 (50%)3/5 (60%)1/1 (100%)2/2 (100%)2/2 (100%)Lactic acidosis10/11 (91%)4/6 (67%)4/5 (80%)1/1 (100%)---2/2 (100%)Cerebellar atrophy6/11 (54%)^a^4/5 (80%)3/5 (60%)------2/2 (100%)Basal ganglia5/11 (45%)------------1/2 (50%)^a^Lacking information from one patientFig. 1Cerebral magnetic resonance (MR) findings. **a** Axial T1W, **b** axial FLAIR, **c** DWI from Patient 1 at neonatal stage, and **d** axial T2W at follow-up; **e** axial T1W and **f** MR spectroscopy (MRS) at basal ganglia at neonate and **g** axial T1W at infant stages from Patient 4; **h** coronal T2W, **i** sagittal T1W, **j** axial T2W, **k** axial T1W from Patient 11. MR features include cerebellar atrophy (white arrows) (**h**, **i**) with progression (**e**, **g**); cerebral atrophy with frontal and anterior temporal lobar predominance (**i**--**k**); thinning of the corpus callosum (**i**); white matter loss and cystic change with frontal predominance (asterisks) (**j**, **k**); basal ganglia involvement with restricted diffusion and cystic change on follow-up (curved arrows) (**a**--**d**); lactate peak at around 1.3 ppm on MRS (arrowheads) (**f**)Fig. 2Pedigrees of 9 families with 11 subjects described in our study

Patient 1 {#Sec3}
---------

Patient 1 was a male with an antenatal history of oligohydramnios and intrauterine growth restriction (IUGR). He was born at 38 weeks. At 7 days old, he developed recurrent episodes of apnea, decreased activity, and mild lactic acidemia. On day 14, he developed circulatory collapse with severe metabolic acidosis and lactic acidosis up to 28.36 mmol/L (reference range 0.5--2.20), hypotension requiring multiple inotropes, an episode of pulseless ventricular tachycardia, and respiratory failure requiring intubation and ventilator support. Thereafter, he developed recurrent convulsions controlled by phenobarbitone and levetiracetam. MRI of the brain at 3 weeks of age showed symmetrical T1 and T2 hyperintensity with restricted diffusion at bilateral lentiform nuclei. Foci of restricted diffusion were also detected at bilateral frontal white matter (Fig. [1a--c](#Fig1){ref-type="fig"}). Magnetic resonance spectroscopy (MRS) showed raised lactate peaks at bilateral basal ganglia and cerebral white matter. Subsequent follow-up MRI showed established infarcts with cystic changes at bilateral lentiform nuclei (Fig. [1d](#Fig1){ref-type="fig"}). Mild cerebellar hypoplasia was also noted. Serial echocardiography in the following months showed progressive septal and ventricular myocardial hypertrophy. WES identified compound heterozygous mutations in *COQ4*, a missense c.370G\>A, p.(Gly124Ser) and a splicing mutation c.402+1G\>C. Functional analysis of the skin fibroblasts showed ETC complex II+III deficiency due to low CoQ concentration. At 5 months of age, CoQ10 supplement up to 40 mg/kg/day. At 8 months, in view of poor neurological prognosis and poor response to CoQ10 treatment, he was diverted to comfort care and extubated. He passed away shortly from respiratory failure.

Patient 2 {#Sec4}
---------

Patient 2 was a term newborn male. He developed respiratory distress, hypotension, and progressive metabolic acidosis with a lactate level of 2.6 mmol/L and hyperalaninemia requiring intubation and inotropic support on day 1 of life. Echocardiogram revealed hypertrophic cardiomyopathy. Plasma amino acids revealed high alanine, proline, and tyrosine, and acylcarnitine profile was unremarkable. CoQ10 supplement at 15 mg/kg/day and carnitine at 100 mg/kg/day were tried on his second day of life but the patient succumbed. WES revealed compound heterozygous mutations in *COQ4*: a missense c.370G\>A, p.(Gly124Ser) and a splicing mutation of c.402+1G\>C.

Patient 3 {#Sec5}
---------

Patient 3 was born full term at 37 weeks. She developed transient respiratory distress shortly after birth. On day 22 of life, she had cardiogenic shock. Echocardiogram showed poor contractility with a left ventricular ejection fraction of 20% and a moderate pericardial effusion. There was associated lactic acidemia (24 mmol/L; reference range 0.5--2.2) and hyperammonemia (139 µmol/L; reference range \<100). She was empirically given CoQ10 supplementation and intravenous immunoglobulin. Her cardiac function improved gradually and normalized by day 32 of life. She developed seizures at 4 months of age requiring multiple anticonvulsants. She is severely delayed developmentally. WES revealed a homozygous *COQ4* mutation c.370G\>A, p.(Gly124Ser).

Patient 4 and Patient 5 {#Sec6}
-----------------------

Patient 4 was the younger sister of Patient 5. She had antenatal history of IUGR and was born at 38 weeks. Immediately postnatal, she developed respiratory distress with intermittent apnea and lactic acidemia (up to 10 mmol/L; reference range 0.5--2.2). MRI brain showed symmetrical T1 hyperintensity at bilateral basal ganglia, with mild cerebellar hypoplasia (Fig. [1e](#Fig1){ref-type="fig"}). MRS showed raised lactate peaks at bilateral basal ganglia (Fig. [1f](#Fig1){ref-type="fig"}). She developed treatment-resistant seizures at 2 months of age. Subsequent MRI at 9 months of age showed generalized progressive cerebellar and cerebral atrophy, with diffuse white matter loss including thinning of the corpus callosum. Cystic changes were seen within the cerebral white matter, bilateral basal ganglia, and thalami (Fig. [1g](#Fig1){ref-type="fig"}). Serial echocardiogram showed progressive moderate left ventricular hypertrophy. Owing to the recognizable clinical presentation, Sanger sequencing was performed and revealed compound heterozygous *COQ4* mutation: c.370G\>A, p.(Gly124Ser) and c.402+1G\>C. CoQ10 supplement has been started since age of 4 years 5 months.

Patient 5 was the elder sister of Patient 4. She was born at 39 weeks with an antenatal history of IUGR. She developed seizures from 2 months of age with associated lactic acidosis and respiratory failure requiring home ventilation. Chest radiograph showed cardiomegaly. CoQ10 supplementation was tried at 1 year of age but passed way from respiratory failure 1 month after. After the genetic diagnosis of her younger sister, Sanger sequencing was performed retrospectively and revealed the same compound heterozygous *COQ4* mutation as her sister, c.370G\>A, p.(Gly124Ser) and c.402+1G\>C.

Patient 6 {#Sec7}
---------

Patient 6 presented at 8 months of life with severe global developmental delay, microcephaly, generalized dystonia, cortical visual impairment, and oromotor dysfunction. Metabolic workup revealed lactic acidemia of 2.5--5.9 mmol/L and hyperalanemia (626 µmol/L; reference range 143--439). WES revealed compound heterozygous mutations in the *COQ4* gene: c.550T\>C, p.(Trp184Arg) and c.402+1G\>A. Functional analysis of the skin fibroblasts showed ETC complex II+III deficiency with low CoQ concentration. There was no further follow-up because of overseas adoption.

Patient 7 {#Sec8}
---------

Patient 7 was a girl, born full term. She had bilateral cortical visual impairment since birth and progressive oromotor dysfunction requiring gastrostomy feeding. She had severe global developmental delay. She developed generalized dystonia and spasticity around 5 months of age. Lactic acidemia of 2.4--3.2 mmol/L was present. WES revealed a homozygous variant in the *COQ4* gene: c.370G\>A, p.(Gly124Ser). Functional analysis of the skin fibroblast showed ETC complex II+III deficiency and low CoQ concentration. She had been on CoQ10 supplement since 2 years old. There was no clinical improvement and the patient died at 3 years and 6 months of age.

Patient 8 {#Sec9}
---------

Patient 8 is a girl, born full term. She developed infantile spasms at 6 months of age. Metabolic workup showed lactic acidemia at 2.2--4.2 mmol/L and hyperalanemia (487 µmol/L; reference range 143--439). WES revealed compound heterozygous variants of the *COQ4* gene c.371G\>T, p.(Gly124Val) inherited from the mother and c.370G\>A, p.(Gly124Ser) inherited from the father. Interestingly, respiratory chain enzymology of the skeletal muscle activities was normal but skin fibroblast functional analysis showed ETC complex II+III deficiency and low CoQ10 concentration. CoQ10 supplement has been given since 9 months of age, with subjective improvement in responsiveness. She is alive and has achieved fair seizure control with levetiracetam and global developmental delay.

Patient 9 {#Sec10}
---------

Patient 9 is a boy, born full term at 40 weeks. He presented with infantile spasms at 2 months of age. CoQ10 supplementation started at 7 years of age and has remained stable. WES revealed a homozygous *COQ4* mutation, c.370G\>A, p.(Gly124Ser). Skin fibroblast functional analysis showed ETC complex II+III deficiency and low CoQ concentration.

Patient 10 and Patient 11 {#Sec11}
-------------------------

Patient 10 is the younger sister of Patient 11. She was born at 36 weeks. She developed transient respiratory distress after birth. She was asymptomatic until 2 months of age when she developed progressive hypotonia, cortical visual impairment, severe developmental delay, and seizures requiring multiple anticonvulsants. Her echocardiogram showed progressive dilated cardiomyopathy and mitral regurgitation. WES revealed a homozygous *COQ4* mutation: c.370G\>A, p. (Gly124Ser). CoQ10 supplement at 30 mg/kg/day was started at 11 months of age, and her seizure control improved.

Patient 11 is the elder sister of Patient 10. She was born full term. At 4 months of age, she presented with seizures, hypotonia, spasticity, oromotor dysfunction, and severe developmental delay. She also developed an episode of acute myocarditis during which her echocardiogram showed diastolic dysfunction. Brain MRI at 14 months showed mild cerebellar atrophy and cerebral atrophy, white matter cystic changes with bilateral frontal and anterior temporal predominance, and thinning of the corpus callosum. Basal ganglia and brainstem appeared preserved (Fig. [1h--k](#Fig1){ref-type="fig"}). No lactic acidosis was detected. Owing to the exome findings of her sister, Sanger sequencing was performed and revealed a homozygous *COQ4* mutation: c.370G\>A, p.(Gly124Ser). She was not on CoQ10 supplement and passed away at 20 months due to an episode of sepsis.

Results {#Sec12}
=======

Pathogenicity of the COQ4 variants {#Sec13}
----------------------------------

We analyzed the COQ4 variants identified in our cohort by previously reported literatures, ClinVar, population frequency in gnomAD,^[@CR7]^ conversation score by Combined Annotation-Dependent Depletion,^[@CR8]^ in silico prediction by Rare Exome Variant Ensemble Learner,^[@CR9]^ and protein stability change prediction by STRUM^[@CR10]^ (Table [3](#Tab3){ref-type="table"}). All variants demonstrated a deleterious effect. Together with the reduced level of CoQ10 of the patients, the pathogenicity of these variants is strongly supported by the biochemical findings of the patients.Table 3Analysis of the four variants identified in our cohortVariantgnomAD population frequencyReported to be disease causing?CADDREVELddGc.370G\>A, p.(Gly124Ser)1.13e−04Yes (Lu et al.^[@CR6]^)24.80.817−1.19c.402+1G\>C2.79e−05Yes (ClinVar)28.8N/AN/Ac.371G\>T, p.(Gly124Val)3.98e−06No24.60.753−1.53c.550T\>C, p.(Trp184Arg)0No26.70.538−0.62*CADD* Combined Annotation-Dependent Depletion, *REVEL* Rare Exome Variant Ensemble Learner, *N/A* not available

Founder mutation analysis {#Sec14}
-------------------------

Among these 11 patients, we identified the same missense mutation c.370G\>A, p.(Gly124Ser) in 10 of them. This missense mutation is a rare variant with a population frequency of 0.001118 and it is exclusively found in South East Asians in the gnomAD database.^[@CR7]^ Further analysis of the DNA of the five homozygous patients using Infinium OmniZhongHua-8 BeadChip SNP array showed a common haplotype of 0.464--3.290 cM implying that the mutation was inherited from a common ancestor 27 generations ago (Fig. [3](#Fig3){ref-type="fig"}). In addition, by principal component analysis), our SNP array data are clustered with Chinese and Japanese of HapMap Phase II (*n* = 270) and a local southern Chinese database (*n* = 612). Furthermore, the pathogenicity of this mutation has been established via the reduced CoQ level in the skin fibroblasts in Patients 7 and 9 who have homozygous c.370G\>A mutation (Table [4](#Tab4){ref-type="table"}). Altogether our study confirms that the missense mutation c.370G\>A, p.(Gly124Ser) represents a pathogenic founder mutation in the southern Chinese population.Fig. 3Founder mutation analysis. Shared haplotypes among homozygous COQ4:c.370G\>A. Red square indicates the location of homozygous COQ4:c.370G\>A, while black square indicates the nearest heterozygous single-nucleotide polymorphism. The length of the haplotype for each subject is at the right panel. The maximum shared length is approximately 577 kbTable 4COQ level in the skin fibroblasts in patients with *COQ4* mutationPatientTissueCOQ levelCICI+IIICIICII+IIICIIICIV1Skin fibroblast0.4 pmol/U COX (1.64--3.32)NormalNot doneNormal130 mU/U COX (269--781)NormalNormal6Skin fibroblast0.63 pmol/U CS (1.04--2.92)NormalNot doneNormal183 mU/U COX (269--781)NormalNormal7Skin fibroblast0.4 pmol/UCOX (1.64--3.32)Not doneNot doneNormal183 mU/UCOX (269--781)NormalNot done8Muscle191 pmol/mg (140--580)NormalNot doneNormalNot doneNormalNormalSkin fibroblast0.29 nmol/UCOX (1.64--3.32)NormalNot doneNormal135 mU/U COX (control 269--781 in the skin)NormalNormal9Skin fibroblast16.4 ng/mg prot (46.1 ± 3)Not done64% of CS90% of CS55% of CSNot done67% of CSReference values are given in brackets. Experiment performed at the Radboud University Medical Centre, Nijmegen and the National Taiwan University Hospital*CI* complex I, *CII* complex II, *CIII* complex III, *CIV* complex IV, *CS* citrate synthase

Discussion {#Sec15}
==========

To our knowledge, this is the largest case series of primary COQ10D7 reported. In the literature, primary COQ10D7 cases have been described predominantly with a neonatal onset, with only two cases of childhood onset.^[@CR2]--[@CR5],[@CR8]^ In this study, we have expanded the phenotypic spectrum of primary COQ10D7 from neonatal to infantile onset.

We have five patients exhibiting the well-described neonatal presentation of COQ10D7 as in the literature, characterized by respiratory distress, encephalopathy, seizures, hypotonia, and cardiomyopathy. Previously, it was believed that phenotypes from affected males with *COQ4* mutation would be more severe and highly likely lethal.^[@CR3],[@CR6]^ However, in our study the male-to-female death ratio was 2:3.

We have six patients with infantile-onset phenotypes. Unlike those of neonatal onset, MRI brain for those infantile-onset patients did not show characteristic basal ganglia lesions. Dystonia was observed in two out of the six patients with infantile-onset presentation in our cohort, and it was also observed in the two neonatal-onset cases reported by Lu et al.^[@CR8]^ but not reported in non-Chinese patient.

A summary of the predominant phenotypes in the spectrum of neonatal, infantile, and childhood onset of COQ10D7 is shown in Fig. [4](#Fig4){ref-type="fig"}. The variegated symptoms and disease onsets explain the frequent delay of diagnoses of COQ10D7. This also highlights the importance of the complementarity of biochemical screening for children with unexplained neurological disturbances and the prompt application of WES in order to reach a genetic diagnosis that has an impact on patient management.Fig. 4Phenotypic spectrum of neonatal, infantile, and childhood onset of COQ10D7 from all the reported cases including this study. †Lactic acidosis is not mentioned in the childhood-onset cases. (The color intensity representing the percentage of patients having that clinical presentation in arbitrary form)

Functional analysis to demonstrate the deficiency of CoQ should be carefully examined because mitochondrial enzymology can be tissue specific. In this study, among the five patients (Patients 1, 6, 7, 8, 9) with ETC chain analysis in the skin fibroblast, all of them shown a reduced level of succinate:cytochrome *c* oxidoreductase (complex II+III). Measurement of CoQ level was also found significantly decreased. For Patients 7 and 8, complex II+III analysis and CoQ level measurement were also performed in the muscle. Interestingly, the CoQ level from the muscle is normal but that from skin fibroblasts was reduced. From the Genotype-Tissue Expression (GTex) data, the *COQ4* median expression in the muscle is 7.58 transcripts per million (TPM) while in the skin it is 44.14 TPM, demonstrating a 6-fold lower expression in the muscle.

More significantly, we have identified a common founder pathogenic *COQ4* mutation associated with COD10D7. In this study, 10 out of the 11 patients carry the *COQ4*: c.370G\>A, p.(Gly124Ser) allele. This mutation fulfills the criteria of a founder mutation: (1) all patients with the mutant alleles share a haplotype associated with the mutation; (2) the haplotype is shared among affected families with a genetic distance \>1 cM; (3) the mutant allele is rare and specific to the population; and (4) all carriers are delineated to the same geographic region. It is likely that this founder mutation causes a relatively higher rate of COQ10D7 in southern Chinese individuals, and that may explain why we can present a larger cohort as compared to past studies in this field.

CoQ10 oral supplementation was previously reported effective in *COQ4* mutation cases.^[@CR2]--[@CR4],[@CR6]^

Among the 10 patients who received CoQ10 supplement and with continuous follow-up, those shown with stabilized cardiac condition or seizure control are those of genotype of homozygous missense variant c.370G\>A (Patients 3, 9, 10). Another patient on CoQ supplement with improved clinical condition is Patient 8 with genotype of compound heterozygous missense variants c.370G\>A/c.371G\>T. For those without improvement are patients with genotype in the presence of a splicing mutation c.402+1G\>A (Patients 1, 2, 4, 5, 6). Among these five patients, three of them (Patients 1, 2, and 5) died from the disease. Retrospectively, Patients 1, 4, and 5 were documented IUGR antenatally. This may suggest that the presence of c.402+1G\>A, a loss-of-function mutation, would cause more severe neonatal onset of phenotypes and less responsive to CoQ10 supplement.

In this study, we have expanded the phenotypic spectrum of *COQ4* mutation. Now COQ10D7 can range from neonatal, infantile to childhood onset. We have also identified a pathogenic *COQ4* founder mutation in the southern Chinese population. The importance of complementarity of biochemical screening and prompt application of WES on patients with unexplained neurological symptoms is highlighted.
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